Table 1.

Baseline demographic and clinical characteristics

Komodo (1 January 2015-30 April 2023)Acentrus (1 January 2016-30 April 2022)
Overall populationHigh CV risk subgroup Overall populationHigh CV risk subgroup 
n = 3342n = 2640n = 1171n = 724
Age (y) at index date, mean ± SD 67.5 ± 10.6 69.4 ± 10.3 70.4 ± 9.9 75.0 ± 7.8 
Female, n (%) 1258 (37.6) 993 (37.6) 405 (34.6) 239 (33.0) 
Year of index date, n (%)     
2016 403 (12.1) 315 (11.9)  
2017 724 (21.7) 579 (21.9) 82 (7.0) 48 (6.6) 
2018 552 (16.5) 441 (16.7) 285 (24.3) 155 (21.4) 
2019 449 (13.4) 347 (13.1) 359 (30.7) 233 (32.2) 
2020 515 (15.4) 401 (15.2) 275 (23.5) 183 (25.3) 
2021 397 (11.9) 315 (11.9) 136 (11.6) 85 (11.7) 
2022 273 (8.2) 215 (8.1) 34 (2.9) 20 (2.8) 
2023 29 (0.9) 27 (1.0) 
US region, n (%)     
West 521 (15.6) 390 (14.8) 394 (33.6) 210 (29.0) 
South 1021 (30.6) 814 (30.8) 323 (27.6) 205 (28.3) 
Midwest 829 (24.8) 653 (24.7) 305 (26.0) 221 (30.5) 
Northeast 845 (25.3) 684 (25.9) 36 (3.1) 20 (2.8) 
Puerto Rico 7 (0.2) 6 (0.2) 
Unknown 119 (3.6) 93 (3.5) 113 (9.6) 68 (9.4) 
Quan-CCI, mean ± SD 3.0 ± 1.5 3.1 ± 1.6 3.0 ± 1.7 3.5 ± 1.9 
Comorbidities, n (%)     
Patients at high risk of a CV event  2640 (79.0) 2640 (100.0) 724 (61.8) 724 (100.0) 
Valvular disease 351 (10.5) 351 (13.3) 58 (5.0) 54 (7.5) 
Renal impairment/dialysis 218 (6.5) 197 (7.5) 47 (4.0) 43 (5.9) 
Atrial fibrillation 254 (7.6) 254 (9.6) 85 (7.3) 85 (11.7) 
Insurance coverage, n (%)     
Medicare 1180 (35.3) 1077 (40.8) 278 (23.7) 202 (27.9) 
Commercial 1094 (32.7) 731 (27.7) 
Managed Care 100 (8.5) 31 (4.3) 
Medicaid 221 (6.6) 181 (6.9) 18 (1.5) 5 (0.7) 
Other 574 (17.1) 431 (16.3) 414 (35.4) 249 (34.4) 
Unknown 273 (8.2) 220 (8.3) 361 (30.8) 237 (32.7) 
Race, n (%)     
White 510 (43.6) 317 (43.8) 
Black 53 (4.5) 39 (5.4) 
Asian 34 (2.9) 22 (3.0) 
Other 574 (49.0) 346 (47.8) 
Komodo (1 January 2015-30 April 2023)Acentrus (1 January 2016-30 April 2022)
Overall populationHigh CV risk subgroup Overall populationHigh CV risk subgroup 
n = 3342n = 2640n = 1171n = 724
Age (y) at index date, mean ± SD 67.5 ± 10.6 69.4 ± 10.3 70.4 ± 9.9 75.0 ± 7.8 
Female, n (%) 1258 (37.6) 993 (37.6) 405 (34.6) 239 (33.0) 
Year of index date, n (%)     
2016 403 (12.1) 315 (11.9)  
2017 724 (21.7) 579 (21.9) 82 (7.0) 48 (6.6) 
2018 552 (16.5) 441 (16.7) 285 (24.3) 155 (21.4) 
2019 449 (13.4) 347 (13.1) 359 (30.7) 233 (32.2) 
2020 515 (15.4) 401 (15.2) 275 (23.5) 183 (25.3) 
2021 397 (11.9) 315 (11.9) 136 (11.6) 85 (11.7) 
2022 273 (8.2) 215 (8.1) 34 (2.9) 20 (2.8) 
2023 29 (0.9) 27 (1.0) 
US region, n (%)     
West 521 (15.6) 390 (14.8) 394 (33.6) 210 (29.0) 
South 1021 (30.6) 814 (30.8) 323 (27.6) 205 (28.3) 
Midwest 829 (24.8) 653 (24.7) 305 (26.0) 221 (30.5) 
Northeast 845 (25.3) 684 (25.9) 36 (3.1) 20 (2.8) 
Puerto Rico 7 (0.2) 6 (0.2) 
Unknown 119 (3.6) 93 (3.5) 113 (9.6) 68 (9.4) 
Quan-CCI, mean ± SD 3.0 ± 1.5 3.1 ± 1.6 3.0 ± 1.7 3.5 ± 1.9 
Comorbidities, n (%)     
Patients at high risk of a CV event  2640 (79.0) 2640 (100.0) 724 (61.8) 724 (100.0) 
Valvular disease 351 (10.5) 351 (13.3) 58 (5.0) 54 (7.5) 
Renal impairment/dialysis 218 (6.5) 197 (7.5) 47 (4.0) 43 (5.9) 
Atrial fibrillation 254 (7.6) 254 (9.6) 85 (7.3) 85 (11.7) 
Insurance coverage, n (%)     
Medicare 1180 (35.3) 1077 (40.8) 278 (23.7) 202 (27.9) 
Commercial 1094 (32.7) 731 (27.7) 
Managed Care 100 (8.5) 31 (4.3) 
Medicaid 221 (6.6) 181 (6.9) 18 (1.5) 5 (0.7) 
Other 574 (17.1) 431 (16.3) 414 (35.4) 249 (34.4) 
Unknown 273 (8.2) 220 (8.3) 361 (30.8) 237 (32.7) 
Race, n (%)     
White 510 (43.6) 317 (43.8) 
Black 53 (4.5) 39 (5.4) 
Asian 34 (2.9) 22 (3.0) 
Other 574 (49.0) 346 (47.8) 

Demographic characteristics were evaluated on the date of treatment initiation. Clinical characteristics were evaluated in the 12-month baseline period.

SD, standard deviation.

See supplemental Table 2 for details regarding the definition of patients at high risk for a CV event.

Reference: Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.

or Create an Account

Close Modal
Close Modal